I
ALLO icon

InceptionR’s Allogene Therapeutics ALLO Stock Holding History

InceptionR’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,062
Closed -$25.8K – 623
2024
Q2 		$25.8K Sell
11,062
-22,257
-67% -$65.7K 0.01% 567
2024
Q1 		$149K Buy
+33,319
New +$139K 0.04% 530
2023
Q3 		– Sell
-16,203
Closed -$80.5K – 389
2023
Q2 		$80.5K Buy
+16,203
New +$87.6K 0.04% 392
2023
Q1 		– Sell
-16,488
Closed -$104K – 422
2022
Q4 		$104K Buy
+16,488
New +$153K 0.05% 359

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

InceptionR's ALLO Position: Q3 2024 in Review

InceptionR sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 11,062 shares — an estimated $25.8K sold.

InceptionR first reported a position in ALLO in Q4 2022 and held it in 4 quarters. The position peaked at $149K in Q1 2024. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • InceptionR reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • InceptionR sold 11,062 Allogene Therapeutics shares in Q3 2024, an estimated $25.8K.
  • InceptionR first reported a position in Allogene Therapeutics in Q4 2022 and held it in 4 quarters.
  • InceptionR's Allogene Therapeutics position peaked at $149K in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on InceptionR's 13F filing for Q3 2024, filed 8 Nov 2024.